Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

This article was originally published in The Tan Sheet

Executive Summary

Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
Advertisement

Related Content

PDUFA meeting
PDUFA meeting
PDUFA meeting
NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th
NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th
NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th
Sens. McCain, Schumer Sponsor Generic Drug Approval Acceleration Bill
GPIA/NPA Merger Seeks Unified Generic Industry Voice, Without NAPM
GPIA/NPA Merger Seeks Unified Generic Industry Voice, Without NAPM

Topics

Advertisement
UsernamePublicRestriction

Register

PS091683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel